[1]于立友,汪龙德△,张晶,等.化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*[J].西部中医药,2013,26(10):84-87.
　YU Liyou,WANG Longde,ZHANG Jing,et al.Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(10):84-87.
点击复制

化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年10期
页码:
84-87
栏目:
出版日期:
2013-10-15

文章信息/Info

Title:
Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern
文章编号:
1004-6852(2013)10-0084-04
作者:
于立友，汪龙德△，张晶，刘俊宏
甘肃中医学院附属医院，甘肃 兰州 730020
Author(s):
YU Liyou, WANG Longde△, ZHANG Jing, LIU Junhong
Affiliated Hospital to Gansu University of Traditional Chinese Medicine, Lanzhou 730020, China
关键词:
肝纤维化; 化纤保肝方; 气滞血瘀; 临床研究
Keywords:
hepatic fibrosis;  HuaQian BaoGan Prescription;  Qi staganation and blood stasis pattern;  clinical study
分类号:
R575
文献标志码:
B
摘要:
目的：观察化纤保肝方治疗气滞血瘀型肝纤维化的疗效。方法：将45例肝纤维化患者随机分为治疗组17例，对照组16例，空白组12例。空白组给予基础保肝治疗：口服硫普罗宁片 0.1 g /次，3次/d；治疗组在基础治疗基础上加用化纤保肝方（胶囊剂），4粒/次，3次/d；对照组在此基础上加用扶正化瘀胶囊，5粒/次，3次/d，3组均以治疗12周为1个疗程。1个疗程后观察3组患者治疗前后症状评分的变化，肝功能、肝纤4项、血清转化生长因子β1(TGF-β1)、血小板衍生生长因子(PDGF)、肿瘤坏死因子α(TNF-α)等基因表达以及瞬时弹性检测仪检测的Fibroscan值的变化。结果：治疗组在改善肝纤维化患者的症状、恢复肝功能、降低肝纤4项指标，抑制TGF-β1、PDGF、TNF-α等基因的表达、降低Fibroscan值方面明显优于空白组(P＜0.05)，与对照组比较，差异无统计学意义(P＞0.05)，但明显优于空白组。结论：化纤保肝方具有很好的抗肝纤维化作用。
Abstract:
Objective: To verify clinical effects of HuaQian BaoGan prescription for hepatic fibrosis of Qi staganation and blood stasis pattern. Method: All 45 patients were randomized into 17 cases in the treatment group, 16 cases in the control group and 12 cases in the blank group. The blank group received routine treatment of liver protection; oral tiopronin tablets, each time 0.1g, three times per day; the treatment group took HuaQian BaoGan prescription (capsule), four pills each time, three times per day; the control group took FuZheng HuaYu capsule, five pills each time, three times per day. Twelve weeks were one course of treatment. After one course of treatment, the changes of symptom scales before and after treating, liver function index, four indexes of hepatic fibrosis, genetic expressions including transforming growth factor β1 (TGF-β1), platelet-derived growth factor (PDGF), tumor necrosis factor α (TNF-α) were observed as well as the change of Fibroscan value was detected with instant detector. Result: The treatment group was obviously superior to the blank group in improving the symptoms of patients suffering from hepatic fibrosis, liver function recovery, decreasing four indexes of hepatic fibrosis, inhibiting genetic expressions including TGF-β1, PDGF, TNF-α and others, lowering Fibroscan value (P＜0.05), the difference had no statistical meaning compared with the control group(P＞0.05), but obviously better than the blank group. Conclusion: HuaQian BaoGan prescription shows better effects against hepatic fibrosis.

相似文献/References:

[1]刘成,杨宗国,陆云飞,等.消黄方对大鼠胆汁淤积性肝纤维化的干预作用*[J].西部中医药,2012,25(11):14.
　LIU Cheng,YANG Zong-guo,LU Yun-fei,et al.Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats[J].Western Journal of Traditional Chinese Medicine,2012,25(10):14.
[2]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2014,27(06):13.
　GUO Shouqiang.The Effects of Matrine on the Expressions of TGF-β1 of the Rats with Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2014,27(10):13.
[3]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(10):84.
[4]陈耀章,李根旺.冬虫夏草对心肝肾的保护作用研究[J].西部中医药,2016,29(04):127.
　CHEN Yaozhang,LI Genwang.Study on the Protective Effects of DongChong XiaCao to Heart, Liver and Kidney[J].Western Journal of Traditional Chinese Medicine,2016,29(10):127.
[5]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(10):149.
[6]段桂姣,王振常,吴珊珊.柔肝化纤颗粒对肝纤维化模型大鼠肝组织超氧化物歧化酶和丙二醛的影响[J].西部中医药,2022,35(04):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
　DUAN Guijiao,WANG Zhenchang,Wu Shanshan.Effects of Rougan Huaxian Granules on SOD and MDA in Liver Tissue of Rats with Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(10):30.[doi:10.12174/j.issn.2096-9600.2022.04.08]
[7]徐俊,戚璐,许杰,等.抗纤软肝颗粒对肝纤维化小鼠肠道黏膜通透性的影响[J].西部中医药,2022,35(07):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
　XU Jun,QI Lu,XU Jie,et al.Influence of Anti-fibrosis Liver-softening Granules on Intestinal Mucosal Permeability in Hepatic Fibrosis Mice[J].Western Journal of Traditional Chinese Medicine,2022,35(10):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
[8]李莎,焦战,陈青,等.瞬时弹性成像技术评价自拟中药治疗肝纤维化的临床疗效[J].西部中医药,2020,33(08):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
　LI Sha,JIAO Zhan,CHEN Qing,et al.Clinical Effects of Selfmade Herbs in Treating Liver Fibrosis Evaluated by Transient Elastography[J].Western Journal of Traditional Chinese Medicine,2020,33(10):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
[9]陈懿榕,阙任烨,刘进锴,等.柴胡皂苷d对大鼠肝星状细胞TGFβ-Smad信号通路mRNA表达的影响[J].西部中医药,2022,35(08):15.[doi:10.12174/j.issn.2096-9600.2022.08.04]
　CHEN Yirong,QUE Renye,LIU Jinkai,et al.Influence of Saikosaponins-d on the Expressions of TGFβ-Smad Signal Path mRNA in Rat Hepatic Stellate Cells[J].Western Journal of Traditional Chinese Medicine,2022,35(10):15.[doi:10.12174/j.issn.2096-9600.2022.08.04]
[10]郭召平,苏琴,黄天生.化痰助运通络方治疗痰瘀互结型非酒精性脂肪肝肝纤维化临床研究[J].西部中医药,2021,34(05):122.[doi:10.12174/j.issn.2096-9600.2021.05.31]
　GUO Zhaoping,SU Qin,HUANG Tiansheng.Clinical Study on Treating Non Alcoholic Fatty Liver Fibrosis of Phlegm and Blood Stasis Pattern by Resolving-phlegm Promoting-transportation Dredging-collateral Prescription[J].Western Journal of Traditional Chinese Medicine,2021,34(10):122.[doi:10.12174/j.issn.2096-9600.2021.05.31]

备注/Memo

备注/Memo:
收稿日期：2013-01-21 *基金项目：兰州市科技计划项目(编号2011-2-40) 作者简介：于立友(1987—)，男，硕士学位，医师。研究方向：脾胃病的中医药防治。 △通讯作者：汪龙德(1965—)，男，主任医师。研究方向：脾胃病的中医药防治。
更新日期/Last Update: 2013-10-15